Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.67 |
| ▸ | LCK | P06239 | 16/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1540030 | 1.00 | MAPK14 (0.67) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL4234911 | 0.91 | MAPK14 (0.57) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL1539959 | 0.91 | LCK (0.58) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL14416598 | 0.87 | MAPK14 (0.70) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL31728413 | 0.87 | MAPK14 (0.70) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL1147098 | 0.87 | MAPK14 (0.70) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL29698124 | 0.86 | MAPK14 (0.69) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL1539936 | 0.86 | MAPK14 (0.69) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL28425094 | 0.85 | MAPK14 (0.49) | MAPK14LCKMAPK13EGFRFYN | |
| SCHEMBL11929051 | 0.85 | LCK (0.50) | MAPK14LCKMAPK13EGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994050-A | Dasatinib intermediate Synthesis method of intermediate | 扬州市普林斯医药科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-114634421-A | Preparation method of dasatinib intermediate | 济宁晟泰药业有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-109796448-B | Preparation process of dasatinib | 山东罗欣药业集团股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-118994050-B | Dasatinib intermediate Synthesis method of intermediate | 扬州市普林斯医药科技有限公司 | 2026-03-27 | — | — | CN | disclosed |
| WO-2025231563-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND THEIR USE AS PHARMACEUTICALS | UNIVERSITE DE MONTREAL (CA) | 2025-11-13 | — | — | WO | disclosed |
| CN-119841819-A | Degradation agent for targeting BCR-ABL and application thereof | 北京大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-118994050-A | Dasatinib intermediate Synthesis method of intermediate | 扬州市普林斯医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994050-A | Dasatinib intermediate Synthesis method of intermediate | 扬州市普林斯医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-115028678-B | Bifunctional molecule based on VHL ligand-induced BCR-ABL protein degradation, and preparation method and application thereof | 杭州医学院 | 2024-09-06 | — | — | CN | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225972-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-115028678-A | Bifunctional molecule based on BCR-ABL protein degradation induced by VHL ligand and preparation method and application thereof | 杭州医学院 | 2022-09-09 | — | — | CN | disclosed |
| CN-111212833-B | Phenylpyridine derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2022-09-06 | — | — | CN | disclosed |
| CN-114634421-A | Preparation method of dasatinib intermediate | 济宁晟泰药业有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-109796448-B | Preparation process of dasatinib | 山东罗欣药业集团股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109796448-B | Preparation process of dasatinib | 山东罗欣药业集团股份有限公司 | 2022-05-10 | — | — | CN | disclosed |